Meningioma

She’s a female ( more liable to meningioma d2 high estrogen receptors ) Her young age suggests meningioma Presence of calcifications Most probably the answer is B (@asma_ashraf63)

This is actually a microcystic meningioma. Thin-walled structures containing grungy proteinaceous pink stuff, not dense reddish material (secretory) or RBCs (angiomatous). Gain of chromosome 5 is common. Great guesses, everyone! (@CraigHorbinski)

This is psamomatous meningioma (@ibo_dimma)

Secretory meningioma (@Nisha81472187)

Chordoid meningioma.Smarce1 mutation. (@ArchanabAol27)

Microcystic Meningioma? (@vaghasiyaviren)

secretary meningioma (@NewjobiRakesh)

Secretory meningioma (@BarathiNataraj)

Secretory meningioma! KLF4 and TRAF7 mutations. (@nusrat_xahra)

I cocked up a meningioma in my exam. (called it craniopharingioma) Marked as wrong but not dangerous. (I suck on neuropath) (@daninava)

Yes meningioma 😀 (@Histopatolomon)

Meningioma (@SaikatM70644742)

fibrous meningioma (@BlankaFlama)

Yes - as a bonus I had brain surgery 10 months ago to remove a meningioma tumor that was a little larger than a golf ball. Neurosurgeon said it had been growing for 10-15 yrs to get that big. If not for having Covid it would have been found later & bigger. (@Seussrn1)

Interesting caseseries by Dr. Hintz, @AnujGoenkaMD & colleagues · Somatostatin receptor type 2 present in nearly all meningiomas · 68Ga-DOTATATE, a PET radiotracer, binds to this receptor with high affinity (@PDBrownOnc)

Honored to have worked together with such a brilliant group of people! Thanks for all the guidance @jana_ivanidze 🙏 I also hope our work will be impactful in promoting DOTATATE’s availability for meningioma RT planning #IvanidzeLab (@JoseA_Rodr)

JUST LAUNCHED - NRG-BN003 now has a patient study webpage. Learn more about the trial for patients with newly diagnosed grade 2 meningiomas that appear to have been completely removed through surgery. https://t.co/cwRfQkojUy #BrainCancer @DrVogelbaum @MoffittNews (@NRGonc)

@WilliamCChen1 presenting his award-winning research on a biomarker that predicts #meningioma radiation response at #ASCO2023. Photo credit to @J_deGrootMD @JennieWTaylor and Susan Chang! @NeurosurgUCSF @UCSFCancer @UCSF (@LabRaleigh)

@WilliamCChen1 from @LabRaleigh presenting his award winning #meningioma radiation-response biomarker research at #ASCO2023! Photo credit to @J_deGrootMD @JennieWTaylor and Susan Chang! @NeurosurgUCSF @UCSFCancer @UCSF (@LabRaleigh)

Very excited for this special #Meningioma issue in #Neurosurgery Clinics Thank you @DoctorZada & @rljensenmdphd for the opportunity to contribute + thank you to all additional contributing authors for making this a great issue! #Braintumor #Braincancer #BTAM #BTSM https://t.co/aELqG2RXDJ (@NeuroOncSurgery)

Excited for the latest issue of #Neurosurgery Clinics focusing on #Meningioma, co-edited by @rljensenmdphd & myself 🙏🏼 Drs. @RussellLonser, Dan Resnick & contributing authors. https://t.co/8mNRifdoC1 @USCBTC @NeurosurgeryUSC @KeckMedUSC @KECKSchool_USC @Meningioma_host (@DoctorZada)

Happy to read this paper. We clearly need a molecular-based classification for meningiomas (@gminniti2012)

I was going with meningioma.. :p (@DrJPLow)

?Meningioma (@VHNguyenMD)

Thank you so much @jimpearson_nico. We @OSUWexMed @OSUCCC_James @NeurosurgeryOSU are working with @OhioStatePath Dr. #JoseOtero and @GlauciaMariad16 to make a difference to our patients with #meningiomas. This is just the beginning. (@PrevedelloDanny)

I didn't know that. ・Neurofibromas and malignant schwannomas (MPNST) in NF1 ・Neurofibroma and meningioma in NF2 (Note that schwannoma, neurofibroma and MPNST are different, though they can be lumped together as neurinoma) https://t.co/TmuYnWcSmS (@shubababan)

CD34 and STAT-6 diffusely positive. There is also some positivity for SSTR2A... SFT vs Meningioma? @JMGardnerMD @SteveBillingsMD @GAGatesDO @01sth02 @JLHornick @JMcMahonG (@JacobSmalberger)

I have an anterior skull base Meningioma with this mutation (SMO) (@SnarkyAbby)

Radiologically it would look extra-axial. GFAP, EMA, SSTR2 immunostains would all help. Methylation profiling would also reliably discriminate between meningioma and glioma. (@CraigHorbinski)

Meningioma, EMA+, MUC4+. Great images. (@RZitwer)

SSTR2A along w BAP1 (LOE). This is a Rhabdoid meningioma (@NabilTabish)

BAP1 loss. Don’t have EMA and PR. Patient had history of meningioma (@MTaherianMD)

Read our Oct 1 issue! 📗 https://t.co/muAe7yL07c In this issue: ✅@d__with et al on trends in #meningioma & vestibular #schwannoma incidence ✅@TapKadia et al on outcomes in patients w/ newly diagnosed #TP53 mutated AML ✅@ToniaPoteat et al on #BreastCancer care delays (@JournalCancer)

CDKN2A loss is bad for IDHmuntant glioma, terrible for meningioma, and possibly prognostic for IDH-wildtype GBM in our institutional data (https://t.co/VnuX7hamOX). Is there something about it and brain tumor🤔 #noa @AlbertHKimMDPhD @soumon_rudra (@JHuangRadonc)